12 recruiting. 12 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 12 |
| Phase 1 | 6 | Recruiting 6 |
| Phase 3 | 2 | Recruiting 2 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV) | Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-08-21 | 2026-09-15 |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis Obinutuzumab - Granulomatosis With Polyangiitis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2025-12-19 | 2026-03-06 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 8 | 2024-11-29 | 2025-04-11 |
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NKX019, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | Nkarta, Inc. | 240 | 2024-11-04 | 2026-10-30 |
| Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) CD19- BCMA CAR-T cells - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2024-10-15 |
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8) · Lupus Erythematosus, Systemic (5) · Myositis (5) · Scleroderma, Systemic (5) · Dermatomyositis (4) · Granulomatosis with Polyangiitis (4) · Arthritis, Rheumatoid (3) · Polymyositis (3) · Sjogren's Syndrome (3) · Antiphospholipid Syndrome (2) · Scleroderma, Diffuse (2) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Autoimmune Diseases (1) · Behcet Syndrome (1)
Cardiovascular Diseases (12) · Immune System Diseases (12) · Skin Diseases (12) · Skin Diseases, Vascular (12) · Skin and Connective Tissue Diseases (12) · Vascular Diseases (12) · Autoimmune Diseases (11) · Vasculitis (11) · Connective Tissue Diseases (8) · Muscular Diseases (8) · Musculoskeletal Diseases (8) · Nervous System Diseases (8) · Neuromuscular Diseases (8) · Arthritis (6)
Abatacept (1) · Adalimumab (1) · Azathioprine (1) · Certolizumab Pegol (1) · Cyclophosphamide (1) · Cyclosporine (1) · Etanercept (1) · Glucocorticoids (1) · Hydroxychloroquine (1) · Immunotherapy, Adoptive (1) · Infliximab (1) · Interleukin 1 Receptor Antagonist Protein (1) · Leflunomide (1) · Methotrexate (1) · Mycophenolic Acid (1)
Assistance Publique - Hôpitaux de Paris (1) · Cartesian Therapeutics (1) · Chinese PLA General Hospital (1) · Essen Biotech (1) · Fate Therapeutics (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · NYU Langone Health (1) · Nkarta, Inc. (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · Robert Spiera, MD (1)
China (5) · United States (5) · France (1) · Italy (1)
Jonathan Samuels, MD (1) · Lindsay Lally, MD (1) · Maria Antonietta D'Agostino (1) · Robert F Spiera, MD (1) · Zhanguo Li (1)